[1]吴 兵,杨学龙,孙 峰.抗VEGF药物治疗视网膜静脉阻塞的效果[J].医学信息,2023,36(23):73-76.[doi:10.3969/j.issn.1006-1959.2023.23.018]
　WU Bing,YANG Xue-long,SUN Feng.Effect of Anti-VEGF Drugs in the Treatment of Retinal Vein Occlusion[J].Journal of Medical Information,2023,36(23):73-76.[doi:10.3969/j.issn.1006-1959.2023.23.018]
点击复制

抗VEGF药物治疗视网膜静脉阻塞的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年23期
页码:
73-76
栏目:
论著
出版日期:
2023-12-01

文章信息/Info

Title:
Effect of Anti-VEGF Drugs in the Treatment of Retinal Vein Occlusion
文章编号:
1006-1959（2023）23-0073-04
作者:
吴 兵; 杨学龙; 孙 峰
（南京市高淳人民医院眼科，江苏 南京 211300）
Author(s):
WU Bing; YANG Xue-long; SUN Feng
(Department of Ophthalmology,Nanjing Gaochun People’s Hospital,Nanjing 211300,Jiangsu,China)
关键词:
视网膜静脉阻塞; 抗血管内皮生长因子药物; 最佳矫正视力; 脉络膜血管指数
Keywords:
Retinal vein occlusion; Anti-vascular endothelial growth factor drugs; Best corrected vision; Choroidal vascular index
分类号:
R774
DOI:
10.3969/j.issn.1006-1959.2023.23.018
文献标志码:
A
摘要:
目的 研究抗血管内皮生长因子（VEGF）药物对视网膜静脉阻塞（RVO）的治疗效果。方法 以2020年6月-2022年9月南京市高淳人民医院眼科收治的35例RVO患者为研究对象（共35眼），按病理分型可分为缺血型（18例）与非缺血型（17例），按血管阻塞部位可分为网膜中央静脉阻塞（CRVO）16例与视网膜分支静脉阻塞（BRVO）19例，采用抗VEGF药物眼内注射治疗，比较不同类型RVO患者治疗前后最佳矫正视力（BCVA）、光学相干断层扫描（OCT）指标[黄斑中心凹厚度（CMT）、黄斑中心凹下脉络膜厚度（SFCT）、脉络膜血管指数（CVI）]。结果 缺血型与非缺血型RVO患者治疗后BCVA均高于治疗前，CMT、SFCT、CVI均小于治疗前，且非缺血型RVO患者BCVA高于缺血型RVO患者，CMT、SFCT、CVI小于缺血型RVO患者（P＜0.05）；CRVO与BRVO患者治疗后BCVA均高于治疗前，CMT、SFCT、CVI均小于治疗前，且BRVO患者BCVA高于CRVO患者，CMT、SFCT、CVI小于CRVO患者（P＜0.05）。结论 抗VEGF药物在不同类型RVO患者中均具有良好治疗效果，但对于非缺血型RVO患者及BRVO患者临床获益更多。
Abstract:
Objective To study the therapeutic effect of anti-vascular endothelial growth factor (VEGF) drugs on retinal vein occlusion (RVO).Methods Thirty-five RVO patients (35 eyes) admitted to the Department of Ophthalmology, Nanjing Gaochun People’s Hospital from June 2020 to September 2022 were selected as the research objects. According to the pathological classification, they were divided into ischemic type (18 patients) and non-ischemic type (17 patients). According to the site of vascular obstruction, they were divided into 16 patients of central retinal vein occlusion (CRVO) and 19 patients of branch retinal vein occlusion (BRVO). They were treated with anti-VEGF drugs by intraocular injection. The best corrected visual acuity (BCVA) and optical coherence tomography (OCT) indexes [central macular thickness (CMT), subfoveal choroidal thickness (SFCT), choroidal vascular index (CVI)] of patients with different types of RVO before and after treatment were compared.Results The BCVA of patients with ischemic and non-ischemic RVO after treatment was higher than that before treatment, and CMT, SFCT and CVI were lower than those before treatment, while the BCVA of patients with non-ischemic RVO was higher than that of patients with ischemic RVO, and CMT, SFCT and CVI were lower than those of patients with ischemic RVO (P<0.05). The BCVA of CRVO and BRVO patients after treatment was higher than that before treatment, and CMT, SFCT and CVI were lower than those before treatment. The BCVA of BRVO patients was higher than that of CRVO patients, and CMT, SFCT and CVI were lower than those of CRVO patients (P<0.05).Conclusion Anti-VEGF drugs have good therapeutic effects in patients with different types of RVO, but they have more clinical benefits for patients with non-ischemic RVO and BRVO.

参考文献/References:

[1]王少龙,孙艳,侯宁,等.视网膜分支静脉阻塞抗VEGF治疗患者脉络膜血管指数的变化及其临床意义[J].山东医药,2022,62(28):34-37.[2]付燕,杨娜,李丽英,等.抗血管内皮生长因子药物治疗对视网膜静脉阻塞合并黄斑水肿患眼脉络膜厚度的影响[J].中华眼底病杂志,2021,37(9):681-686.[3]陈冬军,刘彦,陈建华.不同雷珠单抗玻璃体腔注射方案治疗视网膜分支静脉阻塞继发黄斑水肿的疗效及其对黄斑血流密度的影响[J].川北医学院学报,2022,37(7):852-855.[4]熊鑫,雷颖庆,田敏,等.不同抗VEGF药物治疗视网膜静脉阻塞继发黄斑水肿疗效的系统评价[J].中国循证医学杂志,2021,21(12):1416-1423.[5]陈丽莉,赵键.雷珠单抗治疗视网膜静脉阻塞合并黄斑水肿的疗效[J].中国临床医生杂志,2021,49(10):1246-1249.[6]陈露璐,陈有信.2019年《EURETINA视网膜静脉阻塞诊疗指南》解读[J].中华实验眼科杂志,2020,38(1):60-63.[7]赵娟,毕晓达,司艳芳,等.雷珠单抗注射液治疗非缺血型视网膜分支静脉阻塞黄斑水肿患者的临床研究[J].中国临床药理学杂志,2021,37(11):1330-1332.[8]陈光,石荣兴,王旭凯,等.玻璃体腔注射雷珠单抗对视网膜静脉阻塞眼部血流动力学的影响[J].医学研究与教育,2020,37(6):35-41.[9]欧玉仑,周小平,谢丽莲,等.抗VEGF联合激光治疗视网膜静脉阻塞合并黄斑水肿[J].国际眼科杂志,2019,19(7):1162-1165.[10]李丽萍,赵洪超,张云珠,等.抗VEGF治疗视网膜静脉阻塞伴黄斑水肿患者疗效及预后影响因素[J].昆明医科大学学报,2020,41(8):52-57.[11]刘珏,陈再洪.雷珠单抗治疗非缺血型视网膜分支静脉阻塞继发黄斑水肿的疗效观察[J].海南医学院学报,2020,26(2):126-132.[12]林红,曾继红,骆洪梅.康柏西普或雷珠单抗治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J].局解手术学杂志,2019,28(11):882-885.[13]马为梅,李春花,雷晓琴,等.雷珠单抗玻璃体腔按需注射治疗视网膜分支静脉阻塞继发黄斑水肿疗效研究[J].陕西医学杂志,2019,48(11):1552-1555.[14]黄韵洁,陈晓隆.雷珠单抗和康柏西普对视网膜分支静脉阻塞合并黄斑水肿效果分析[J].中国药物与临床,2019,19(20):3585-3587.[15]Okamoto M,Yamashita M,Sakamoto T,et al.Choroidal blood flow and thickness as predictors for response to anti-vascular endothelial growth factor therapy in macular edema secondary to branch retinal vein occlusion[J].Retina,2018,38(3):550-558.[16]Okamoto M,Yamashita M,Ogata N.Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema[J].Graefes Arch Clin Exp Ophthalmol,2018,256(5):885-892.[17]Aribas YK,Hondur AM,Tezel TH.Choroidal vascularity index and choriocapillary changes in retinal vein occlusions[J].Graefes Arch Clin Exp Ophthalmol,2020,258(11):2389-2397.[18]赵旭丽,阳光,张娣,等.康柏西普与雷珠单抗治疗非缺血型视网膜分支静脉阻塞继发黄斑水肿的对比观察[J].中国眼耳鼻喉科杂志,2019,19(1):39-42.[19]贾媛媛,喻晓兵,叶红,等.玻璃体腔注射雷珠单抗治疗缺血型和非缺血型视网膜中央静脉阻塞继发黄斑水肿一年疗效对比观察[J].中华眼底病杂志,2018,34(5):443-447.[20]陈蓓,陈凡.非缺血型视网膜分支静脉阻塞黄斑水肿抗VEGF治疗的疗效研究[J].国际眼科杂志,2019,19(3):426-429.

相似文献/References:

[1]陈 行,汤永强.缓释制剂在眼科疾病治疗中的应用研究[J].医学信息,2021,34(02):65.[doi:10.3969/j.issn.1006-1959.2021.02.018]
　CHEN Hang,TANG Yong-qiang.Study on the Application of Sustained-release Preparations in the Treatment of Ophthalmic Diseases[J].Journal of Medical Information,2021,34(23):65.[doi:10.3969/j.issn.1006-1959.2021.02.018]
[2]司 昕,高 磊,高荣玉,等.视网膜静脉阻塞后视网膜缺血的研究现状[J].医学信息,2021,34(15):25.[doi:10.3969/j.issn.1006-1959.2021.15.007]
　SI Xin,GAO Lei,GAO Rong-yu,et al.Current Research Status of Retinal Ischemia After Retinal Vein Occlusion[J].Journal of Medical Information,2021,34(23):25.[doi:10.3969/j.issn.1006-1959.2021.15.007]
[3]陆耀楠,庞燕华.视网膜静脉阻塞的治疗现状和进展[J].医学信息,2023,36(14):178.[doi:10.3969/j.issn.1006-1959.2023.14.039]
　LU Yao-nan,PANG Yan-hua.Current Status and Progress in the Treatment of Retinal Vein Occlusion[J].Journal of Medical Information,2023,36(23):178.[doi:10.3969/j.issn.1006-1959.2023.14.039]

更新日期/Last Update: 1900-01-01